1. Poland Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Selvita SA

Selvita SA

4.23
EUR
+0.00
(-0.12%)
-0.03EPS
132.87MMarket Cap
Nov 19Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.55
2.99
3.39
4.39
- -
7.98
16.94
19.65
18.89
18.63
19.84
18.44
Basic EPS, GAAP
0.39
0.17
0.24
0.65
- -
1.05
0.81
1.65
3.81
-0.33
0.04
-0.11
Free Cash Flow per Basic Share
-1.33
-1.53
0.56
0.24
- -
0.83
3.27
-1.42
0.27
2.47
3.6
2.4
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.89
3.44
2.21
2.87
2.58
8.02
10.73
14.28
17.82
17.54
17.53
17.19
Tangible Book Value per Share
2.74
3.03
2.19
2.85
2.53
7.98
4.52
8.14
12.28
11.18
11.36
7.84
Basic Weighted Avg Shares
16
16
16
16
5
17
18
18
18
18
18
18
Sales/Revenue/Turnover
41
48
55
71
- -
137
311
361
347
342
364
338
Operating Margin (%)
5.21
-14.93
12.33
15.78
- -
14.24
8.39
11.07
4.83
-0.14
3.44
2.64
Depreciation Expense
3
4
3
5
- -
14
27
37
45
53
54
53
Net Income, GAAP
6
3
4
10
- -
18
15
30
70
-6
1
-2
Effective Tax Rate (%)
- -
- -
17.95
1.88
- -
- -
13.51
19.4
- -
- -
- -
- -
Profit Margin (%)
15.28
5.65
7.19
14.85
- -
13.1
4.79
8.4
20.15
-1.78
0.22
-0.62
Working Capital
32
29
30
33
21
110
83
80
57
-81
5
-6
LT Debt
- -
8
1
6
18
28
145
172
178
76
118
101
Total Equity
47
56
37
49
45
153
206
273
327
322
322
315
Return on Invested Capital (%)
- -
- -
10.38
22.31
- -
- -
7.72
7.26
- -
- -
- -
- -
Return on Capital (%)
- -
- -
6.98
20.04
- -
- -
5.13
7.2
- -
- -
- -
- -
Return on Common Equity (%)
- -
5.34
8.63
25.64
- -
19.09
8.66
13.21
23.72
-1.88
0.25
-0.66

Capital Structure

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
52
57
70
LT Borrowings
75
71
67
LT Finance Leases
43
40
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
18
18
Market Capitalization
794
651
571

Working Capital

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
127
120
125
Cash, Cash Equivalents & STI
24
20
17
Accounts Receivable, Net
68
64
69
Inventories
8
9
9
Total Current Liabilities
122
121
131
Payables & Accruals
- -
- -
- -
ST Debt
52
57
70
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
33.58%
17.13%
-0.05%
Free Cash Flow
- -
179.88%
45.73%
Net Income, GAAP
- -
-1.06%
-113.33%
Sales/Revenue/Turnover
- -
28.72%
6.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
76
80
88
97
342
2025
90
93
88
93
364
2026
76
82
- -
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.12
-0.55
0.13
0.2
-0.33
2025
-0.05
-0.25
-0.05
0.4
0.04
2026
-0.3
-0.17
- -
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Boguslaw Sieczkowski
Full Time Employees
899
Sector
Health technology
Industry
Biotechnology
Address
Hexagon Kraków MA Poland 30-394
IPO Date
Oct 16, 2019
Website
selvita.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Selvita S.A. (WSE: SLV) operates as a leading preclinical contract research organization (CRO), providing comprehensive drug discovery and development services to pharmaceutical and biotechnology companies worldwide; core offerings include AI-driven drug discovery, medicinal and synthetic chemistry, computer-aided drug design, structural biology, in vitro and in vivo pharmacology, ADME/DMPK studies, analytical testing, bioanalytical analysis, high-throughput screening, and bioinformatics platforms powered by machine learning and data analytics. The company serves therapeutic areas such as oncology and immunology, with target markets encompassing data-driven life science and healthcare organizations across Europe and the United States; it maintains operations through over 900 employees at six sites in four countries, including headquarters in Krakow, Poland, additional facilities in Poznan and Wroclaw, Poland, and offices in Boston Area, San Francisco Area, and Cambridge, UK. Founded in 2007, Selvita focuses on bridging early drug discovery to clinical stages, delivering integrated solutions for assay development, stability studies, quality control, and regulatory support. Recent developments include the 2024 acquisition of PozLab, which expands small molecule drug manufacturing for early-stage clinical trials and adds laboratory space in Poznan; launch of new sites in Poznan and Wroclaw targeting high-margin CDMO and biological drug discovery; and strengthened management in sales and drug development, with PozLab expected to contribute positively to operating profit by end-2025 amid an 11% backlog increase for the year.

Company News

Company News APIChatGPT

  • gurufocus.com

    Selvita reports Q1 2026 results and launches strategic options review

  • prnewswire.com

    Selvita reports Q1 2026 results and launches strategic options review